The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism

Pharmacogenetics

Volumn 6, Issue 4, 1996, Pages 341-349

  Sullivan Klose, Theresa H ^a,b   Ghanayem, Burhan I ^a   Bell, Douglas A ^a   Zhang, Zhi Yi ^c   Kaminsky, Laurence S ^c   Shenfield, Gillian M ^d   Miners, John O ^e   Birkett, Donald J ^e   Goldstein, Joyce A ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c WADSWORTH CENTER   (United States)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

CYP2C9; Polymorphism; Tolbutamide

Indexed keywords

CYTOCHROME P450 ISOENZYME; DNA; LEUCINE; RADIOISOTOPE; TOLBUTAMIDE; WARFARIN; CYP2C9 PROTEIN, HUMAN; CYTOCHROME P450; RECOMBINANT PROTEIN; STEROID 16ALPHA MONOOXYGENASE; STEROID MONOOXYGENASE; UNSPECIFIC MONOOXYGENASE;

ALLELE; ARTICLE; CAUCASIAN; CHINESE; DRUG METABOLISM; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYDROXYLATION; NONHUMAN; NORMAL HUMAN; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; YEAST; ASIAN; GENETICS; METABOLISM; NEGRO;

AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LEUCINE; RECOMBINANT PROTEINS; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TOLBUTAMIDE;

EID: 0029658591     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199608000-00007     Document Type: Article

References (38)

1. Brian WR, Srivastava PK, Umbenhauer DR, Lloyd RS, Guengerich FP. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 1989: 28, 4993-4999.
2. Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR. Genetic and metabolic criteria for the assignment of debrisoquine hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1991: 1, 33-41.
3. de Morais SMF, Schweikl H, Blaisdell J, Goldstein JA. Gene structure and upstream regulatory regions of human CYP2C9 and CVP2C18. Biochem Biophys Res Commun 1993: 194, 194-201.
4. de Morais SMF, Goldstein JA, Xie HG, Huang SL, Lu YQL, Xia H, Xiao ZS, Ile N, Zhou HH. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995: 58, 404-11.
5. 180 → Cys) determines the polymorphism in cytochrome P450g (P4502C13) by altering protein stability. J Biol Chem 1992: 267, 2032-2037.
6. Furya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ, Idle JR. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulant therapy. Pharmacogenetics 1995: 5, 389-392.
7. Ged C, Umbenhauer DR, Bellew TM, Bork RW, Srivastava P, Shinriki N, Lloyd RS, Guengerich FP. Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4′-hydroxylase. Biochemistry 1988: 27, 6929-6940.
8. Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 8th edition. New York: Pergamon Press Inc., 1990.
9. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994: 4, 285-299.
10. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Raucy JL, Kitareewan S, Lasker JM, Ghanayem B. Evidence for a role for 2C19 in metabolism of S-mephenytoin in humans. Biochemistry 1994: 33, 1743-1752.
11. Haining RL, Veronese ME, Trager WF, Rettie AE. Baculovirus-mediated expression and purification of the I359L allelic variant of CYP2C9: evaluation of substrate and product stereo-selectivity. Presented at the Fourth International ISSX meeting Seattle, Washington (August 27-31, 1995) (Abstract).
12. Inaba T. Phenytoin: Pharmacogenetic polymorphism of 4′-hydroxylation. Pharmacol Ther 1990: 46, 341-347.
13. Kaminsky LS, Fasco MJ, Guengerich FP. Production and application of antibodies to rat liver cytochrome P-450. Methods Enzymol 1981: 74, 262-272.
14. Kaminsky LS, de Morais SMF, Faletto MB, Dunbar D, Goldstein JA. Correlation of human P4502C substrate specificities with primary structure-warfarin as a probe. Mol Pharmacol 1993: 43, 234-239.
15. Kimura S, Pastewka J, Gelboin, HV, Gonzalez, FJ. cDNA and amino acid sequences of two members of the human P450IIC gene subfamily. Nucleic Acids Res 1987: 15, 10053-10054.
16. Kimura S, Umeno M, Skoda RL, Meyer UA, Gonzalez FJ.The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphism CYP2D6 gene, a related gene and a pseudogene. Am J Human Genet 1989: 45, 889-904.
17. Kutt H, Wolk M, Scherman R, McDowell F. Insufficient parahydroxylation as the cause of diphenylhydantoin toxicity. Neutrology 1964: 14, 542-548.
18. Meehan RR, Gosden JR, Rout D, Hastle ND, Friedberg T, Adesnik M, Buckland R, van Heyningen V, Fletcher J, Spurr NK, Sweeney J, Wolf CR. Human cytochrome P-450 PB-1: A multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10. Am J Hum Genet 1988: 42, 26-37.
19. Miners JO, Wing LMH, Birkett DJ. Normal metabolism of debrisoquine and theophylline in a poor hydroxylator of tolbutamide. Aust NZ J Med 1985: 15, 348-349.
20. Mura C, Panserat S, Vincent-Viry M, Galteau MM, Jacqz-Aigrain E, Krishnamoorthy R. DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers. Hum Genet 1993: 92, 367-372.
21. Page MA, Boutagy JS, Shenfield GM. A screening test for slow metabolizers of tolbutamide. Br J Clin Pharmacol 1991: 31, 649-654.
22. Relling MV, Aoyama T, Gonzalez FJ, Meyer UA. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 1990: 252, 442-447.
23. Rettie AE, Korzekwa, R. Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ. Trager WF. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992: 5, 54-59.
24. Rettie A, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994: 4, 39-42.
25. Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 1991: 30, 3247-3255.
26. Scott J, Poffenbarger PL. Pharmacogenetics of tolbutamide metabolism in humans. Diabetes 1979: 28, 41-51.
27. Shimada T, Yamazki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994: 270, 414-423.
28. Srivastava PK, Yun C-H, Beaune PH, Ged C, Guengerich FP. Separation of human liver microsomal tolbutamide hydroxylase and (S)-Mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol Pharmacol 1991: 40, 69-79.
29. Stephens EA, Taylor JA, Kaplan N, Yang CH, Hsieh LL, Lucier GW, Bell DA. Ethnic variation in the CYT2EI gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics 1994: 4, 185-192.
30. Sullivan TH, Birkett DJ, Bell DA, Ghanayem BI, Shenfield GM, Goldstein JA. Determination of CYP2C9 allele frequencies and of a possible role in amino acid substitution in tolbutamide hydroxylase activity. Presented at the fourth International ISSX meeting, Seattle Washington (August 27-31), 1995 (Abstract).
31. Umbenhauer DR, Martin MV, Lloyd RS, Guengerich FP. Cloning and sequence determination of a complementary DNA related to human liver microsomal cytochrome P-450 S-mephenytoin 4-hydroxylase. Biochemistry 1987: 26, 1094-1099.
32. Vasko MR, Dell RD, Daly DD, Pippenger CE. Inheritance of phenytoin hypometabolism: a kinetic study of one family. Clin Pharmacol Ther 1980: 27, 96-103.
33. Vermeij P, Ferrari MD, Buruma OJ, Veenema H, de Wolf FA. Inheritance of poor phenytoin parahydroxylation capacity in a Dutch family. Clin Pharmacol Ther 1988: 44, 588-593.
34. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 1991: 175, 1112-1118.
35. Veronese ME, Miners JO, Rees DLP, Birkett DJ. Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects. Pharmacogenetics 1993a: 3, 86-93.
36. Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DLP, Gasser R, Meyer UA, Birkett DJ. Site directed mutation studies of human liver cytochrome P-450 isozymes in the CYP2C subfamily. Biochem J 1993b: 289, 533-538.
37. Wang SL, Huang JD, Lai MD, Tsai JJ. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995: 5, 37-42.
38. Yasumori TS, Kawano K, Nagata M, Shimada Y, Yamazoe Y, Kato R. Nucleotide sequence of a human liver cytochrome P-450 related to the rat male specific form. J Biochem (Tokyo) 1987: 102, 1075-1082.